trending Market Intelligence /marketintelligence/en/news-insights/trending/7_PEWkyqo_ulARJbEt4Ufw2 content esgSubNav
In This List

Strides Shasun receives US FDA approval for Parkinson's disease treatment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Strides Shasun receives US FDA approval for Parkinson's disease treatment

Strides Shasun Ltd. said the U.S. Food and Drug Administration approved its amantadine hydrochloride capsules USP, 100 milligrams.

The drug, which the company will launch immediately, is used as treatment for Parkinson's disease and as pain reliever in the treatment of shingles.

The U.S. market for the product is about $25 million with three generic players, Strides Shasun said in a news release, citing IMS data.